Myeloid-derived suppressor cells (MDSC) are one of the major components of the tumor microenvironment. The main feature of these cells is their potent immune suppressive activity. MDSC are generated in the bone marrow, and in tumor-bearing hosts, migrate to peripheral lymphoid organs and the tumor to contribute to the formation of the tumor microenvironment. Recent findings have revealed differences in the function and fate of MDSC in the tumor and peripheral lymphoid organs. We review these findings here, and in this context we discuss the current understanding as to the nature of these differences, the underlying mechanisms, and their potential impact on the regulation of tumor progression.
Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are
important regulators of immune responses in cancer and have been directly
implicated in promotion of tumor progression. However, the heterogeneity of
these cells and lack of distinct markers hampers the progress in understanding
of the biology and clinical importance of these cells. Using partial enrichment
of PMN-MDSC with gradient centrifugation we determined that low density PMN-MDSC
and high density neutrophils from the same cancer patients had a distinct gene
profile. Most prominent changes were observed in the expression of genes
associated with endoplasmic reticulum (ER) stress. Surprisingly, low-density
lipoprotein (LDL) was one of the most increased regulators and its receptor
oxidized LDL receptor 1 OLR1 was one of the most overexpressed
genes in PMN-MDSC. Lectin-type oxidized LDL receptor 1 (LOX-1) encoded by
OLR1 was practically undetectable in neutrophils in
peripheral blood of healthy donors, whereas 5–15% of total
neutrophils in cancer patients and 15–50% of neutrophils in
tumor tissues were LOX-1+. In contrast to their
LOX-1− counterparts, LOX-1+ neutrophils had
gene signature, potent immune suppressive activity, up-regulation of ER stress,
and other biochemical characteristics of PMN-MDSC. Moreover, induction of ER
stress in neutrophils from healthy donors up-regulated LOX-1 expression and
converted these cells to suppressive PMN-MDSC. Thus, we identified a specific
marker of human PMN-MDSC associated with ER stress and lipid metabolism, which
provides new insight to the biology and potential therapeutic targeting of these
cells.
In recent years, myeloid-derived suppressor cells (MDSC) have emerged as one of the major inhibitors of immune effector cell function in cancer. MDSC represent a heterogeneous population of largely immature myeloid cells that are characterized by a pathological state of activation and display potent immune suppressive activity. Two major subsets of MDSC have been identified: monocytic (M-MDSC) and polymorphonuclear (PMN-MDSC). PMN-MSDC share phenotypic and morphologic features with neutrophils, whereas M-MDSC are similar to monocytes and are characterized by high plasticity. Differentiation of M-MDSC to macrophages and dendritic cells is shaped by tumor microenvironment. In recent years, the mechanisms of this process start to emerge.
In this study, using single-cell RNA-seq, cell mass spectrometry, flow cytometry, and functional analysis, we characterized the heterogeneity of polymorphonuclear neutrophils (PMNs) in cancer. We describe three populations of PMNs in tumor-bearing mice: classical PMNs, polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), and activated PMN-MDSCs with potent immune suppressive activity. In spleens of mice, PMN-MDSCs gradually replaced PMNs during tumor progression. Activated PMN-MDSCs were found only in tumors, where they were present at the very early stages of the disease. These populations of PMNs in mice could be separated based on the expression of CD14. In peripheral blood of cancer patients, we identified two distinct populations of PMNs with characteristics of classical PMNs and PMN-MDSCs. The gene signature of tumor PMN-MDSCs was similar to that in mouse activated PMN-MDSCs and was closely associated with negative clinical outcome in cancer patients. Thus, we provide evidence that PMN-MDSCs are a distinct population of PMNs with unique features and potential for selective targeting opportunities.
Gamma delta (γδ) T cells infiltrate most human tumors, but current immunotherapies fail to exploit their in situ major histocompatibility complex–independent tumoricidal potential. Activation of γδ T cells can be elicited by butyrophilin and butyrophilin-like molecules that are structurally similar to the immunosuppressive B7 family members, yet how they regulate and coordinate αβ and γδ T cell responses remains unknown. Here, we report that the butyrophilin BTN3A1 inhibits tumor-reactive αβ T cell receptor activation by preventing segregation of N-glycosylated CD45 from the immune synapse. Notably, CD277-specific antibodies elicit coordinated restoration of αβ T cell effector activity and BTN2A1-dependent γδ lymphocyte cytotoxicity against BTN3A1+ cancer cells, abrogating malignant progression. Targeting BTN3A1 therefore orchestrates cooperative killing of established tumors by αβ and γδ T cells and may present a treatment strategy for tumors resistant to existing immunotherapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.